Medicus Pharma Ltd.
MDCX evidence brief
What we can confirm
- BioSniper Score:
- 3.8 / 10
- Market Cap:
- $10.7M
- Lead Asset:
- d-mna (Phase 2)
What it means
What to watch
Prepared research question
What matters most for MDCX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MDCX
Medicus Pharma Ltd. (MDCX) is a biotech/life sciences company advancing clinical development programs for novel therapeutics, including SkinJect for skin cancer and Teverelix for prostate cancer, while repositioning around a new oncology candidate CD228V.
Key risk: Negative shareholders' equity
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$10.7M
Cash Runway
—
Lead Asset
d-mna (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials for Medicus Pharma Ltd..
Similar companies
Medicus Pharma Ltd. (MDCX) is a biotech/life sciences company advancing clinical development programs for novel therapeutics, including SkinJect for skin cancer and Teverelix for prostate cancer, while repositioning around a new oncology candidate CD228V.
- Reported cash & equivalents of $15.2M as of 2026-06-30 [sec].
- Net income of -$11.6M and shareholders' equity of -$1.8M as of 2026-06-30 [sec].
- Raised about $40 million through equity and debt financing during the first half of 2026 [news · published 2026-08-13].
- Repositioning around CD228V, a second-generation antibody-drug conjugate targeting CD228-expressing solid tumors, as its principal oncology candidate [news · published 2026-09-08].
- SkinJect is pursuing a registrational Phase 2b study design (SKNJCT-005) and has filed for Orphan Drug Designation and Rare Pediatric Disease Designation [sec_mda · as of 2026-08-12].
What works
- Raised approximately $40 million through equity and debt financing in the first half of 2026, strengthening financial flexibility [news · published 2026-08-13].
- Received FDA clearance to proceed with a Phase 2b dose-optimization study of Teverelix in men with advanced prostate cancer [sec_mda · as of 2026-08-12].
- Expanding clinical trial sites internationally, including in Europe and the UAE, for SkinJect studies [sec_mda · as of 2026-05-14].
What to weigh
- Shareholders' equity is negative at -$1.8M as of 2026-06-30, indicating liabilities exceed assets [sec].
- Net income of -$11.6M as of 2026-06-30 reflects ongoing operating losses [sec].
- The company's forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
Repositioning around CD228V
“Medicus Pharma (NASDAQ:MDCX) is repositioning itself as a precision oncology-led biotechnology company, centering its strategy on CD228V, a second-generation antibody-drug conjugate targeting CD228-expressing solid tumors”
News · September 8, 2026
Financing raised in first half of 2026
“raising about $40 million through equity and debt financing during the first half of 2026”
News · August 13, 2026
Risks & what to watch (3)›
Key risks
- Negative shareholders' equity — Shareholders' equity of -$1.8M as of 2026-06-30 indicates liabilities exceed assets [sec].
- Operating losses — Net income of -$11.6M as of 2026-06-30 reflects ongoing losses [sec].
- Forward-looking statement risks — Substantial risks and uncertainties could cause actual results to differ materially from projections [sec_mda · as of 2026-08-12].
What to watch
- Progress of the registrational Phase 2b study (SKNJCT-005) for SkinJect and decisions on Orphan Drug and Rare Pediatric Disease Designations [sec_mda · as of 2026-08-12].
- Outcome of the Phase 2b dose-optimization study of Teverelix in advanced prostate cancer [sec_mda · as of 2026-08-12].
- Execution of the repositioning strategy around CD228V and its clinical development [news · published 2026-09-08].
- Ability to manage cash runway given $15.2M cash and ongoing net losses [sec].
Sources: News · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Medicus Pharma Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Medicus Pharma Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$12M
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is the AI investment thesis for Medicus Pharma Ltd.?
Medicus Pharma Ltd. (MDCX) is a biotech/life sciences company advancing clinical development programs for novel therapeutics, including SkinJect for skin cancer and Teverelix for prostate cancer, while repositioning around a new oncology candidate CD228V.
What is Medicus Pharma Ltd.'s lead drug candidate?
Medicus Pharma Ltd.'s most advanced tracked candidate is d-mna (Phase 2) for basal cell carcinoma (BCC) of the skin.
Who is the CEO of Medicus Pharma Ltd.?
Dr. Raza Bokhari M.B.A., M.D. is the chief executive officer of Medicus Pharma Ltd. (MDCX).
Where is Medicus Pharma Ltd. headquartered?
Medicus Pharma Ltd. (MDCX) is headquartered in West Conshohocken, PA, United States.
What therapeutic areas does Medicus Pharma Ltd. focus on?
Medicus Pharma Ltd. develops therapies across Oncology, Ophthalmology, Dermatology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.